Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Orforglipron Receives FDA Approval for Chronic Weight Management
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!The US Food and Drug Administration (FDA) has approved orforglipron (Foundayo), a once-daily oral GLP-1 RA, for chronic weight management in adults with obesity or overweight and ≥1 weight-related comorbidity.1In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA’s decision and the myriad new treatment opportunities afforded by orforglipron’s clearance for entry into the market.The approval of orforglipron is supported by the phase 3 ATTAIN clinical…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.